8-K: MetaVia Announces Positive Phase 1 Trial Results for Obesity Drug DA-1726

MetaVia Inc. reports positive top-line data from its Phase 1 clinical trial of DA-1726, showing compelling weight loss and safety effects for obesity treatment.

Summary

• MetaVia Inc. announced positive results from the Phase 1 clinical trial of DA-1726, a dual agonist for treating obesity.
• The 4-week study showed excellent safety and tolerability with positive clinical activity.
• Subjects receiving 32 mg of DA-1726 experienced a maximum weight reduction of 6.3% and a mean weight reduction of 4.3% at Day 26 (p=0.0005).
• The drug also demonstrated a maximum reduction in fasted glucose of -18 mg/dL and a mean reduction of -5.3 mg/dL at Day 26 at the 32 mg dose.
• Waist circumference reduction showed a maximum of 3.9 inches and a mean of 1.6 inches at Day 33.
• The company plans to conduct a Phase 1 Part 3 study on Wegovy early drop-out patients to explore DA-1726's potential superiority.
• Additional cohorts will be added to the Phase 1 study to determine the maximum tolerated dose.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, highlighting the potential of DA-1726 as a best-in-class obesity drug. The management's comments are optimistic, and the comparison to industry standards suggests a competitive advantage. However, risks related to regulatory approval and financial stability temper the overall sentiment.

Positives

• DA-1726 demonstrated excellent safety and tolerability in the Phase 1 trial.
• The drug showed compelling weight loss effects, with a maximum reduction of 6.3% at the 32 mg dose.
• Fasted glucose was well controlled and showed reduction without any hypoglycemic adverse events.
• Pharmacokinetic results demonstrated a favorable exposure profile and dose proportionality.
• No significant cardiovascular signals were observed.
• The drug may offer superior tolerability compared to currently marketed GLP-1 agonists.
• DA-1726 showed superior body fat mass reduction and lean body mass relative preservation compared to Survodutide in pre-clinical studies.
• DA-1241 Phase 2a top-line data in subjects with presumed MASH met primary end point and showed direct hepatic effects.
• DA-1241 showed significant reductions in HbA1C from baseline at 100 mg dosing at Week 16 compared to the placebo group.

Negatives

• Four out of six subjects on the 32 mg dose experienced mild gastrointestinal adverse events, though most resolved within 24 hours.
• 25% of subjects in the MAD study on DA-1726 experienced mostly mild (GI) related AEs, 12.5% of patients reported nausea (vs. 8.3% on placebo), 16.7% experienced vomiting (vs. 8.3% on placebo), 12.5% experienced constipation and 1 subject experienced abdominal distension.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the ability to obtain regulatory approval and the cooperation of contract manufacturers.
• The company has incurred net losses since inception and anticipates continuing to do so.
• Raising additional capital may cause dilution to existing stockholders.
• Public opinion and scrutiny of treatments for obesity and overweight patients may impact public perception of the Company and DA-1726.
• The company may be required to make significant payments under the 2022 License Agreement.

Future Outlook

The company plans to conduct a Phase 1 Part 3 study on Wegovy early drop-out patients and add additional cohorts to the Phase 1 study to determine the maximum tolerated dose. They are also actively seeking a combination/licensing partner for DA-1241.

Management Comments

• Hyung Heon Kim, President and Chief Executive Officer of MetaVia, stated that the Phase 1 MAD data underscore DA-1726's potential as a best-in-class obesity drug.
• Mr. Kim expressed confidence in DA-1726's potential to become a best-in-class obesity drug with superior tolerability.

Industry Context

The announcement comes amid significant activity in the obesity drug market, with several recent licensing and acquisition deals involving GLP-1 and related agonists. MetaVia is positioning DA-1726 as a potentially best-in-class drug with improved tolerability compared to existing treatments.

Comparison to Industry Standards

• DA-1726 is being compared to drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) in terms of weight loss efficacy.
• The company is aiming for superior tolerability compared to existing GLP-1 agonists, which often have high discontinuation rates due to side effects.
• Pre-clinical data suggests DA-1726 may offer advantages over survodutide in terms of fat mass reduction and lean body mass preservation.
• The company references recent deals such as Novo Nordisk's licensing agreement with United Biotechnology and Roche's acquisition of Carmot Therapeutics to highlight the value of obesity drug assets.

Stakeholder Impact

• Shareholders may benefit from the potential success of DA-1726 and DA-1241.
• Employees may benefit from the company's growth and development.
• Patients may benefit from new and effective treatments for obesity and MASH.

Next Steps

• Conduct a Phase 1 Part 3 study on Wegovy early drop-out patients.
• Add additional cohorts with higher doses to the Phase 1 study to explore the maximum tolerated dose.
• Actively search for a combination/licensing partner for DA-1241.
• Release other exploratory end points including MRI-PDFF at major medical conferences.

Key Dates

Keywords

DA-1726, obesity, GLP-1, glucagon, clinical trial, weight loss, MetaVia, MASH, DA-1241